The alarm call did not go unheard in Germany either: in September, the online portal of Swiss Radio and Television SRF ran with the headline ‘Germany threatens to overtake Switzerland in the pharmaceutical industry’. The background to this was reports of major investments by international pharmaceutical companies north of the Swiss border. The German pharmaceutical industry is currently experiencing a real rush of investment. Pharmaceutical giants Eli Lilly from the USA, Roche from Switzerland and Sanofi from France have invested billions in German locations in recent years. Eli Lilly is building a state-of-the-art production facility for diabetes medication in Alzey, Rhineland-Palatinate, at a cost of 2.3 billion euros. This will create up to 1,000 new jobs.
But that's not all: other companies such as Boehringer Ingelheim and Sanofi have already announced a number of other projects in Germany. Boehringer Ingelheim is expanding its production facilities in Rhineland-Palatinate and is building a new biotechnology centre in Biberach for 350 million euros. In Pfaffenhofen, Bavaria, the Japanese pharmaceutical company Daiichi Sankyo is investing one billion euros in the construction of laboratories for antibody drug conjugates. Roche is also building a gene therapy development centre in Penzberg and investing in the expansion of its production facilities. Bayer will build a new production plant in Berlin worth 130 million euros. Biontech, a leading company in vaccine development, is investing 40 million euros in the expansion of its Marburg production facility and is conducting research in Mainz on novel cancer therapies. These projects show that The German pharmaceutical industry is becoming increasingly interesting for international investors.
Germany is the ideal location for these projects
What makes the location so attractive? Germany is the ideal location for such projects. Lilly chose Germany for good reason. The infrastructure, the political situation and the supply of skilled labour were decisive factors in the choice of location. Germany has a lot to offer, especially in the area of research and development. The German research landscape enjoys an excellent reputation worldwide and is outstandingly networked with numerous universities, institutes and companies. Germany also spends a great deal of money on research and development and leads the way in Europe in terms of patent applications in the healthcare sector.
The German labour market is an additional catalyst for state funding of major investments. Highly qualified specialists in the fields of biotechnology, pharmaceuticals and chemistry are a decisive locational advantage in the increasingly specialised high-tech factories. In addition, there is a lively exchange between pharmaceutical manufacturers and suppliers of pharmaceutical equipment. And what has hardly been noticed in the public perception: Germany still offers a stable regulatory environment for companies that, like the pharmaceutical industry, are confronted with complex approval procedures.
The company leaders also mention the central location and the infrastructure development as arguments in favour of investment. Thanks to its geographical location at the heart of Europe, distribution in the European single market is easy for German companies and the network of fine chemical pre-production, logistics and transport is perfect.